Ronald Herbst

Ronald Herbst has a strong background in scientific and research leadership. Ronald is currently the Chief Scientific Officer at Biolojic Design, Ltd. since October 2022. Prior to this, they served as the Chief Scientific Officer at Pyxis Oncology from 2019 to 2022. Ronald also worked at MedImmune, where they held various roles including VP R&D, Head Oncology Research from 2014 to 2019 and Senior Director from 2011 to 2014. Before joining MedImmune, Ronald Herbst worked at DNAX Research, Inc. (later renamed Schering-Plough Biopharma) as a senior principal investigator from 1997 to 2006. Ronald also worked at DNAX Research Institute/Schering Plough Biopharma as a Staff Scientist and Project Team Leader from 1997 to 2003. Ronald Herbst started their career as a Postdoctoral Fellow at Stanford University's Department of Biological Sciences from 1994 to 1997. Throughout their career, they have demonstrated expertise in oncology research, antibody drug candidates, assay development, and drug discovery.

Ronald Herbst pursued their education in Molecular Biology at Ludwig-Maximilians-Universität München, where they began their PhD in 2005. The duration of their PhD program is not provided, indicating that they may still be pursuing their degree or has completed it but the end year is unknown.